Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis

K Jalaleddini, D Jakimovski, A Keshavan… - Annals of Clinical …, 2024 - Wiley Online Library
Background A quantitative measurement of serum proteome biomarkers that would
associate with disease progression endpoints can provide risk stratification for persons with …

Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis

T Chitnis, F Qureshi, VM Gehman, M Becich… - Nature …, 2024 - nature.com
The multifaceted nature of multiple sclerosis requires quantitative biomarkers that can
provide insights related to diverse physiological pathways. To this end, proteomic analysis of …

Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis

W Zhu, C Chen, L Zhang, T Hoyt, E Walker… - Brain …, 2024 - academic.oup.com
Few studies examined blood biomarkers informative of patient-reported outcome (PRO) of
disability in people with multiple sclerosis (MS). We examined the associations between …

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

D Jakimovski, F Qureshi, M Ramanathan… - Multiple Sclerosis and …, 2024 - Elsevier
Background Brain hypoperfusion is linked with worse physical, cognitive and MRI outcomes
in multiple sclerosis (MS). Understanding the proteomic signatures related to hypoperfusion …

[HTML][HTML] Assessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands

K Sirinukunwattana, C Klein, PFA Clarke… - … Acta Part A: Molecular …, 2025 - Elsevier
Disease modifying therapies including interferon-β (IFNβ) effectively counteract the
inflammatory component in relapsing-remitting multiple sclerosis (RRMS) but this action …

Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation

D Jakimovski, F Qureshi, M Ramanathan… - Journal of the …, 2024 - Elsevier
Background Atrophied lesion volume (aLV), a proposed biomarker of disability progression
in multiple sclerosis (MS) and transition into progressive MS (PMS), depicts chronic …

[引用][C] The Role of Biomarkers in Multiple Sclerosis

MD Kuhle, P Sati - 2024 - MJH Life Sciences